Chengda Pharmaceutical (301201.SZ) released its half-year results, with a net profit attributable to the parent company of 12.8244 million yuan, a year-on-year decrease of 49.06%.

China Finance app news, Chengda Pharmaceutical (301201.SZ) released its semi-annual report for 2025. During the reporting period, the company achieved operating income of 182 million yuan, a year-on-year increase of 11.24%. The net profit attributable to the shareholders of the listed company was 12.8244 million yuan, a year-on-year decrease of 49.06%. The net profit attributable to the shareholders of the listed company after deducting non-recurring gains and losses was 2.899 million yuan, a year-on-year decrease of 8.37%. The basic earnings per share was 0.0847 yuan.